Prevalence of Tumour-Infiltrating CD103+ Cells Identifies Therapeutic-Sensitive Prostate Cancer with Poor Clinical Outcome

Quan Zhou,Yuxi Ou,Xiyu Dai,Xinan Chen,Siqi Wu,Wensun Chen,Mengbo Hu,Chen Yang,Limin Zhang,Haowen Jiang
DOI: https://doi.org/10.1038/s41416-023-02183-4
IF: 9.075
2023-01-01
British Journal of Cancer
Abstract:BACKGROUND: The clinical significance and immune correlation of CD103(+) cells in prostate cancer (PCa) remain explored. METHODS: In total, 1080 patients with PCa underwent radical prostatectomy from three cohorts were enrolled for retrospective analysis. Tumour microarrays were constructed and fresh tumour samples were analysed by flow cytometry. RESULTS: High CD103(+) cell infiltration correlated with reduced biochemical recurrence (BCR)-free survival in PCa. Adjuvant hormone therapy (HT) prolonged the BCR-free survival for high-risk node-negative diseases with CD103(+) cell abundance. CD103(+) cell infiltration correlated with less cytotoxic expression and increased infiltration of CD8(+) and CD4(+) T cells, M1 macrophages and mast cells in PCa. Intratumoral CD8(+) T cell was the predominant source of CD103, and the CD103+ subset of CD8(+) T cells was featured with high IL-10, PD-1 and CTLA-4 expression. Tumour-infiltrating CD103(+) CD8(+) T cells exerted anti-tumour function when treated with HT ex vivo. DISCUSSION: CD103(+) cell infiltration predicted BCR-free survival and response to adjuvant HT in PCa. CD103(+) cell infiltration correlated with an enriched but immune-evasive immune landscape. The study supported a model that CD103 expression conferred negative prognostic impact and immunosuppressive function to tumour-infiltrating CD8(+) T cells, while the CD103(+) CD8(+) T cells exhibited a powerful anti-tumour immunity with response to HT.
What problem does this paper attempt to address?